The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

Not Applicable

Completed

• Conditions: Prostate Cancer; Breast Cancer; Head and Neck Cancer
• Interventions: Procedure: novel PET tracer FACBC

• Registration Number: NCT00605488
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

See where the dye-like material (FACBC) goes in your body and how long it stays in your body. See how much of the dye-like material is picked up by your tumor Compare the FACBC pictures with other pictures (such as FDG PET scan) that were obtained as part of your standard imaging evaluation.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04-25
• Study First Submitted: 2008-01-17
• Study First Submitted QC: 2008-01-30
• Study First Posted: 2008-01-31
• Status Verified: 2017-04
• Primary Completion: 2017-04-06
• Study Completion: 2017-04-06
• Last Update Submitted: 2017-04-07
• Last Update Posted: 2017-04-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Age ≥ or equal 18 years old
• Scheduled for treatment at Memorial Hospital
• Primary HNSCC or primary breast cancer; histological confirmation of diagnosis at Memorial hospital
• Large primary HNSCC cancer (loco-regional advanced, ≥ or equal to T2) by CT/MRI imaging or clinical exam, without prior treatment, N1-N3
• Large primary breast cancer (≥ or equal to T2) by imaging or clinical impression based physical exam; patients with suspicion of axillary nodal disease (N1-2), without prior treatment
• Established progressive metastatic prostate cancer
• This diagnosis may be based upon histologic confirmation of metastatic disease by biopsy of a lesion OR clear clinical evidence for metastatic disease (e.g., based on clinical findings, laboratory data and/or imaging findings in CT, MRI, or bone scan), as defined by the referring oncologist
• Progressive disease is defined as clear progression on imaging studies (increase in size and number of lesions on bone scan, CT, or MRI) and consecutive rises in PSA as used in clinical management by the prostate cancer oncology group at MSKCC
• FDG PET scan was obtained as part of the clinical work-up, within 4 weeks prior to enrollment. This clinical FDG PET scan should be done at MSKCC.
• Disease can be clearly demonstrated by structural imaging (CT or MRI) or bone scan. This may include characteristic bone lesions on bone scan, CT or MRI; AND/OR measurable soft tissue/nodal lesions on CT or MRI.
• Minimum tumor/metastasis size of 1 cm
• Negative pregnancy test

Read More

Exclusion Criteria

• Patient cannot tolerate lying still for approximately 60 minute sessions in the PET tomograph.
• Pregnancy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	novel PET tracer FACBC	Pet Scan

Primary Outcome Measures

Name	Time	Method
To study the biodistribution and dosimetry of FACBC in patients with head and neck squamous cell carcinoma (HNSCC), breast cancer and prostate cancer.	conclusion of study

Secondary Outcome Measures

Name	Time	Method
To compare these FACBC data with PET imaging findings using the current clinical standard PET tracer FDG.	conclusion of study

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States